Easton Pharmaceuticals Announces the Appointment of Evan Karras as CEO / Director and Mr. Nunzio Valerie as President / CFO; Mr. Karras Possesses a Strong Background in Canadian and International Commercial Successes and Is Expected to Make Major Impact on Implementation of Easton’s Business Plan

TORONTO, ON–(Marketwired – Jul 29, 2015) – Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces the appointment of Evan Karras as CEO & Director and announces Mr. Nunzio Valerie as President and Director.

Easton Pharmaceuticals is pleased to announce the appointment of highly successful businessman, Evan Karras as CEO & Director, replacing Carla Pepe, who will assume the role of Secretary and Director. Easton is also pleased to announce the appointment of Mr. Nunzio Valerie, who previously worked as a well respected broker for 14 years as well as holding positions with several venture capital firms. Mr. Valerie will remain as President and has also assumed the position of CFO.

Mr. Karras brings a wealth of knowledge and experience in the implementation of small, medium and large-scale projects on both national and international levels to Easton. A few of Mr. Karras’s significant accomplishments include:

The launch of the first Direct Marketing Company in the Middle East for a personal care products company he founded.

Ranked 35th by Price Waterhouse Cooper among the most respected businessmen during his tenure as President & CEO of Telemax, the largest supplier of prepaid calling products in Canada.

Masters’ degree in Business & Finance.

Other highly successful commercial ventures totalling hundreds of millions of dollars.

Mr. Karras stated, “Timing is everything, and I see this opportunity with Easton Pharmaceuticals as an extremely high-growth undertaking. What especially excites me is that Easton is in a ground-floor position to leverage its partnerships in the Women’s Health arena and make a major impact in the market with the launch of a suite of patented, in-licensed products in Latin America, a unique position when one considers these same licenses were negotiated for in other territories by some of the largest pharma companies in the world.”

Mr. Karras further commented, “Latin America is a very high-growth region for the pharmaceutical industry and I can see additional opportunities for Easton revenues in generic cancer drug sales, as well as with the development of its proprietary cancer compounds. We intend to not only grow in Latin America but across the world in other markets such as the Middle East, and even North America, with some of the other unique product offerings Easton has within the Women’s Health industry.”